Evidence map›Paper›PMID 30796743›Full record

ArticleVirus genes2019

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.

Claudia Alteri, Rossana Scutari, Ada Bertoli, Daniele Armenia, Caterina Gori, Gabriele Fabbri, Claudio Maria Mastroianni, Carlotta Cerva, Antonio Cristaudo, Ilaria Vicenti and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virus genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Claudia AlteriDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy. claudia.alteri@uniroma2.it.
Rossana ScutariDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Ada BertoliDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Daniele ArmeniaDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Caterina GoriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy.
Gabriele FabbriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy.
Claudio Maria MastroianniUniversity of Rome "La Sapienza", Piazzale Aldo Moro 5, 00185, Rome, Italy.
Carlotta CervaInfectious Diseases Unit, University Hospital of Rome "Tor Vergata", Viale Oxford 81, 00133, Rome, Italy.
Antonio CristaudoInfectious Dermatology and Allergology Unit, San Gallicano Dermatological Institute, IFO-IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
Ilaria VicentiDepartment of Medical Biotechnology, University of Siena, Viale Bracci 2, 53100, Siena, Italy.
Bianca BruzzoneHygiene Unit, IRCCS AOU San Martino - IST, Largo R. Benzi 10, 16132, Genoa, Italy.
Maurizio ZazziDepartment of Medical Biotechnology, University of Siena, Viale Bracci 2, 53100, Siena, Italy.
Massimo AndreoniInfectious Diseases Unit, University Hospital of Rome "Tor Vergata", Viale Oxford 81, 00133, Rome, Italy.
Andrea AntinoriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy.
Valentina SvicherDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Carlo Federico PernoDepartment of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milano, Italia.
Maria Mercedes SantoroDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.

Funding

CHAIN 223131Italian Ministry of Health Project n. 2
6 · The paper itself

Abstract

Integrase-strand-transfer inhibitors (INSTIs) are known to rapidly reduce HIV-1 plasma viral load, replication cycles, and new viral integrations, thus potentially limiting viral evolution. Here, we assessed the role of INSTIs on HIV-1 V3 evolution in a cohort of 89 HIV-1-infected individuals starting an INSTI- (N = 41, [dolutegravir: N = 1; elvitegravir: N = 3; raltegravir: N = 37]) or a non-INSTI-based (N = 48) combined antiretroviral therapy (cART), with two plasma RNA V3 genotypic tests available (one before [baseline] and one during cART). V3 sequences were analysed for genetic distance (Tajima-Nei model) and positive selection (dN/dS ratio). Individuals were mainly infected by B subtype (71.9%). Median (interquartile-range, IQR) plasma viral load and CD4 + T cell count at baseline were 4.8 (3.5-5.5) log

Indexed as

DolutegravirDrug Resistance, ViralEvolution, MolecularGenotypeHeterocyclic Compounds, 3-RingHIV-1HIV Envelope Protein gp120HIV InfectionsHIV IntegraseHumansOxazinesPeptide FragmentsPiperazinesPyridonesViral LoadDolutegravirHeterocyclic Compounds, 3-RingHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)HIV IntegraseOxazinesPeptide FragmentsPiperazinesPyridonesHIV-1HIV-1 evolutionHIV-1 tropismIntegrase inhibitorsV3

Identifiers

PMID30796743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.